reports
Molecular Partners presents new preclinical data on Radio-DARPin and S...
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med Additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad ...
Molecular Partners Announces all Board Proposals Approved at Annual Ge...
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority. The Molecular Partners shareholders confirmed the approval of the annua...
Molecular Partners to hold three poster presentations at AACR 2025
Molecular Partners to hold three poster presentations at AACR 2025 Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Switzerland and CONCORD, Mas...
Molecular Partners Publishes Invitation to Annual General Meeting 2025
Molecular Partners Publishes Invitation to Annual General Meeting 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2025. The Annual General Meeting will be held on Wednesday, April 16, 2025, 9.00 CET (doors open at 8.30 CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland. to the Annual General Meeting 2025 with the correspon...
Molecular Partners Reports Highlights from Q4 2024 and Key Financials ...
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on Radio-DARPins now expanded to ten programsMP0533 Phase 1/2a clinical data show improved response rate and depth in ongoing cohort, additional dosing optimization planned; data expected throughout 2025Strong financial position with CHF 149 million in cash, cash equivalents and short-term deposits at end of 2024, expected to support operations well into 2027Conferen...
Molecular Partners Announces Participation at Upcoming Investor Confer...
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upco...
Molecular Partners Outlines Clinical Expansion Plans and Strengthens R...
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano MedOrano Med partnership on Radio-DARPins now expanded to 10 programsMP0533 clinical data show improved response rate and depth in cohort 8 with steeper step-up and more frequent dosing; additional dose densification planned in cohort 9, u...
Molecular Partners and Orano Med expand partnership to develop Targete...
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the parties’ emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med’s expertise in the development of 212Pb-based TAT and vast proprietary supply of 212Pb and Molecular Partners’ unique Radio-DARPins as an ideal vector for radiopharmaceuticalsMost advanced 212Pb-Radio-DARPin, DLL3...
Molecular Partners to Present at JP Morgan Healthcare Conference and B...
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will attend and present the Company’s latest developments and outlook for 2025 at two upcoming investor conferences in January. Baader Helvea Swiss Equities Conference, taking place Ja...
Molecular Partners Presents Clinical Data Supporting its Ongoing MP053...
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process with optimized dosing scheme to overcome target-mediated drug disposition and test the full potential of MP0533 Switch-DARPin MP0621 demonstrates intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen...
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switc...
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a variety of tumor types further evidenced by comprehensive clinical biomarker analyses ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new ...
Molecular Partners Announces Upcoming Poster Presentations at the 65th...
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin MP0621 demonstrates cKit+ cell killing while reducing off-target effects seen with systemic anti-CD47 blockade ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of cu...
Molecular Partners Q3 2024 Interim Management Statement: Multiple Upda...
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025 RDT strategic agreement with Orano Med revised and strengthened: both companies to co-develop four 212Pb-based RDT candidates, including MP0712 MP0533 phase 1 dose escalation study continues; update to be p...
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 21...
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each)Molecular Partners will hold commercial rights to the second nominated Radio-DARPin Candidate, in addition to rights to first program MP0712 targeting DLL3 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – AG (SIX: MOLN; NASDAQ: MOLN),...
Molecular Partners and Orano Med Present Additional Positive Preclinic...
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision attributes for alpha radiation therapy Molecular Partners and Orano Med preparing for clinical entry in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art...
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on M...
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protei...
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
Molecular Partners Reports H1 2024 Corporate Highlights and Financials First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025 Strategic collaboration agreement signed with Orano Med to co-develop 212Pb-based RDT candidates for multiple oncology targets, including MP0712 MP0533 phase 1 dose escalation continues with cohort 8 open; clinical data update on amended dosing scheme expected in 2025 Switch-DARPin Platform: preclinical data supporting mechanism of action of Switch-DARPin concept and of...
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Inno...
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announce that the Company will present in a fireside chat at the 2nd TD Cowen Radiopharmaceutical Innovation Summit today, June 17, 2024 at 10:40 a.m. ET (4:40 p.m. CET). Presenting on behalf of Molecular Partners will be Michael Stumpp, Ph.D., Executive Vice P...
Molecular Partners Presents Positive Preclinical Data for First Switch...
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activatorsPreclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effectsMP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announ...
Molecular Partners and Orano Med Share Positive Preclinical Data of th...
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano MedPositive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profileFirst-in-human study in planning with initial data expected in 2025RDT platform expanding with portfolio of additional targets under evaluation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PAR...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.